Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
Satoshi Takagi(Japanese Foundation For Cancer Research), Ryohei Katayama(Japanese Foundation For Cancer Research), Yosuke Seto, Masanori Saito(Japanese Foundation For Cancer Research), Ai Takemoto(Japanese Foundation For Cancer Research), Kengo Takeuchi(Japanese Foundation For Cancer Research), Seiji Sakata(Japanese Foundation For Cancer Research), Miho Takami(Chemotherapy Foundation), Yoshiya Sugiura(Japanese Foundation For Cancer Research), Keisuke Ae(The Cancer Institute Hospital), Mikako Nakajima(Japanese Foundation For Cancer Research), Sumie Koike, Naoya Fujita(Japanese Foundation For Cancer Research), Satoko Baba(Japanese Foundation For Cancer Research), Yuki Funauchi(Japan Association for Development of Community Medicine)
Cited by 4
Related Papers
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
|Nature Communications|2017|409
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264